Business
RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st
MOUNTAIN VIEW, Calif., May 14, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath©, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer, Shaun Bagai, will participate in a fireside chat at the Alliance Global Partners (A.G.P.) Virtual Healthcare Company Showcase hosted by Scott Henry, Managing Director and Healthcare Analyst at A.G.P., on Ma
About this update from Renovorx, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/3e352c8639f4b6e257b29dc0d8bfbab4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/03lG4NuoBW0vZmMT7xyVjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3e352c8639f4b6e257b29dc0d8bfbab4","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/1e_ez24sVYfz7bluTfn5Vg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/3e352c8639f4b6e257b29dc0d8bfbab4","width":1024,"height":512}},"lazy":false},{"type":"text","content":"MOUNTAIN VIEW, Calif., May 14, 2025--(BUSINESS WIRE)--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath©, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer, Shaun Bagai, will participate in a fireside chat at the Alliance Global Partners (A.G.P.) Virtual Healthcare Company Showcase hosted by Scott Henry, Managing Director and Healthcare Analyst at A.G.P., on May 21, 2025.","length":548,"tagName":"p"},{"type":"text","content":"Mr. Bagai will share recent business developments, highlighting continuing momentum with the Company’s RenovoCath commercialization, as well as progress in the ongoing Phase III TIGeR-PaC clinical trial. TIGeR-PaC is evaluating RenovoRx’s novel drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG) for treatment in locally advanced pancreatic cancer (LAPC), which is currently under investigation, and has not yet been approved for commercial sale.","length":489,"tagName":"p"},{"type":"text","content":"Fireside Chat Details:Date: Wednesday, May 21, 2025Time: 12:40 p.m. ETSpeaker: Shaun Bagai, CEOModerator: Scott Henry, AGP Managing Director and Healthcare AnalystWebcast: https://ir.renovorx.com/news-events/ir-calendar-events","length":231,"tagName":"p"},{"type":"text","content":"To schedule a one-on-one investor meeting with Mr. Bagai, please contact your A.G.P. representative or KCSA Strategic Communications at [email protected].","length":154,"tagName":"p"},{"type":"te...